Promising Phase II Results for AISA-021 in Systemic Sclerosis-Associated Raynaud’s Phenomenon
Berlin, Germany – In a significant development for patients suffering from systemic sclerosis-associated Raynaud’s phenomenon (SSc RP), Aisa Pharma has announced positive results from its Phase II RECONNOITER trial of AISA-021 (cilnidipine). The findings, presented at the 9th World Systemic Sclerosis Congress in Athens, Greece, offer a potential new therapeutic avenue for a condition that significantly impacts quality of life. SSc RP is a debilitating condition characterized by reduced blood flow to the fingers and toes in response to cold or stress, leading to pain, discoloration, and potentially tissue damage. Currently, treatment options are limited, and a dedicated therapy for SSc RP remains unmet medical demand.
The double-blind, randomised, prospective crossover, placebo-controlled trial evaluated the safety and efficacy of daily oral AISA-021 in 64 patients diagnosed with active SSc RP. The study was designed in two parts: Part A assessed optimal dosage (10mg and 20mg), efficacy, and safety when co-administered with a phosphodiesterase type 5 (PDE-V) inhibitor, while Part B, involving 37 patients, employed a crossover design to further evaluate the drug’s effects. Participants continued to receive their standard care alongside AISA-021 during the trial period.
The primary endpoint of the study focused on the change from baseline in the mean weekly number of Raynaud’s attacks experienced by patients. While the primary endpoint did not reach statistical significance, with AISA-021 demonstrating a 22.1% reduction in attack frequency compared to a 12.4% reduction in the placebo group, secondary endpoints revealed encouraging results. These findings suggest a potential benefit of AISA-021 in managing the symptoms of SSc RP.
Significant Improvements in Attack-Free Days and Symptom Severity
Notably, AISA-021 treatment led to a substantial increase in attack-free days, showing a placebo-adjusted rise of over 155% and a nearly four-fold improvement from baseline. This suggests a considerable reduction in the disruptive impact of Raynaud’s attacks on daily life. The trial demonstrated statistically significant reductions in the duration of attacks and improvements in skin temperature at the proximal interphalangeal joint (PIP), a key indicator of blood flow.
Beyond the direct effects on Raynaud’s symptoms, AISA-021 also showed improvements in non-Raynaud’s symptoms as measured by the SHAQ PRO instrument for SSc. Patients receiving AISA-021 reported numerical benefits over placebo in areas such as all-cause pain, gastrointestinal dysfunction, disability, overall disease severity, and breathing difficulties. This suggests a broader positive impact on the overall well-being of individuals living with systemic sclerosis.
The safety profile of AISA-021 was also favorable, with no treatment-related serious adverse events reported across all treatment groups. This is a crucial factor in the development of any new therapy, particularly for chronic conditions requiring long-term treatment. Cilnidipine, the active ingredient in AISA-021, is a calcium channel blocker already approved for the treatment of hypertension in several countries, including Japan, suggesting a degree of established safety.
Next Steps: Regulatory Meetings and Phase III Trial Planning
Following these promising Phase II results, Aisa Pharma plans to engage with the US Food and Drug Administration (FDA) and other regulatory agencies to discuss the findings and outline the plan for a Phase III clinical trial. The goal is to establish a pathway for potential registration of AISA-021 as a treatment specifically for SSc RP. A successful Phase III trial would be a critical step towards making this therapy available to patients who currently have limited treatment options.
Andrew Sternlicht, founder and CEO of Aisa Pharma, emphasized the significance of these findings, stating, “Systemic sclerosis-associated Raynaud’s phenomenon remains a highly burdensome manifestation of scleroderma, with no approved treatment options and significant impact on function and quality of life.” He acknowledged that while the Phase II study did not achieve statistical significance on the primary endpoint, the consistent positive effects observed across multiple endpoints are encouraging. “AISA-021 showed significant improvements in the number of Raynaud’s attack-free days and attack duration, which were higher than those seen with currently available calcium channel blockers. AISA-021 also improved pain and other Raynaud’s symptoms while maintaining a favourable safety profile. These encouraging results provide strong support for advancing to Phase III studies.”
Understanding Systemic Sclerosis and Raynaud’s Phenomenon
Systemic sclerosis (SSc), also known as scleroderma, is a chronic autoimmune disease characterized by hardening and tightening of the skin and connective tissues. The Scleroderma Foundation provides comprehensive information about the disease, its symptoms, and available resources for patients and caregivers. Raynaud’s phenomenon, a common symptom of SSc, causes blood vessels in the extremities to narrow in response to cold or stress, leading to reduced blood flow.
While Raynaud’s phenomenon can occur independently, it is often associated with autoimmune diseases like systemic sclerosis. In SSc-associated Raynaud’s, the condition tends to be more severe and can lead to complications such as digital ulcers (sores on the fingers and toes) and tissue damage. Effective management of SSc RP is crucial to prevent these complications and improve the quality of life for affected individuals.
Current treatment options for Raynaud’s phenomenon typically focus on managing symptoms and preventing complications. These include lifestyle modifications such as keeping warm, avoiding stress, and quitting smoking. Medications such as calcium channel blockers and vasodilators may also be prescribed to improve blood flow. However, these treatments are not always effective, and there is a clear need for more targeted therapies specifically designed for SSc RP.
The development of AISA-021 represents a promising step forward in addressing this unmet medical need. The Phase II trial results suggest that this novel calcium channel blocker may offer a more effective and well-tolerated treatment option for patients with systemic sclerosis-associated Raynaud’s phenomenon. The upcoming Phase III trial will be crucial in confirming these findings and paving the way for potential regulatory approval.
Key Takeaways:
- Aisa Pharma’s AISA-021 showed promising results in a Phase II trial for systemic sclerosis-associated Raynaud’s phenomenon (SSc RP).
- While the primary endpoint wasn’t statistically significant, secondary endpoints demonstrated significant improvements in attack-free days, attack duration, and skin temperature.
- AISA-021 also improved non-Raynaud’s symptoms and exhibited a favorable safety profile.
- The company plans to meet with regulatory agencies to discuss a Phase III trial.
The next step in the development of AISA-021 will be closely watched by the SSc community. Further research and clinical trials are essential to confirm these initial findings and determine the long-term benefits and risks of this potential new therapy. Readers interested in learning more about systemic sclerosis and Raynaud’s phenomenon are encouraged to consult with their healthcare providers and explore resources from organizations like the Scleroderma Foundation.
Do you have experience with systemic sclerosis or Raynaud’s phenomenon? Share your thoughts and questions in the comments below. Please also share this article with anyone who might find this information helpful.
Keep reading